Evaluation of the cyclic combination chemotherapy protocol including doxorubicin effects on cardiac parameters
Guy Tater
Doxorubicin is a commonly used chemotherapy agent for the treatment of canine malignant lymphoma. It is reported to induce cardiotoxic effects when administered in high doses. The aim of this work was to examine whether any cardiac effects can be documented following doxorubicin administration as part of a cyclic
chemotherapy protocol. Dogs were recruited for this work after being diagnosed with canine malignant lymphoma and undergoing a cyclic combination chemotherapy protocol including L-asparaginase, vincristine, cyclophosphamide, prednisolone and doxorubicin.
The first part of this work retrospectively analysed the echocardiographic records of 108 patients. LVFS as the most commonly reported and used method to detect doxorubicin cardiotoxicity, was examined.
Records of dogs presented between the years 2001 to 2010 were reviewed and 446 LVFS measurements from 108 dogs were included. No significant change of the LVFS was documented along the different stages of the chemotherapy protocol. The lower reference value used for LVFS of 25% was not exceeded.
The second part of this work included a prospective study. The aim of this study was to use more advanced and sensitive methods to detect possible cardiac changes and/or damage during the cyclic combination protocol. Fourteen dogs were included.
Blood work was performed prior to inclusion to exclude kidney damage. All dogs underwent an echocardiography examination and ultrasensitive Troponin I sampling prior and post doxorubicin administrations. The echocardiographic examination included standard as well as tissue velocity imaging measurements.
Systolic and diastolic velocity images were examined on interventricular septum and free wall. A total of 182 TVI and 1017 ultrasensitive Tropinin I measurements were performed and evaluated. During the twelve week cyclic combination protocol, Tissue Doppler indices and ultrasensitive Troponin I measurements did not change
significantly.
These findings conclude that the cyclic combination protocol seems to be safe, and no evidence of myocardial damage was detectable using echocardiographic or ultrasensitive Troponin I measurements. Further larger prospective studies should evaluate suspected doxorubicin induced myocardial damage, using sensitive new methods such as strain, strain rate and speckle tracking. Myocardial damage at the cellular level could not be excluded but if present it did not appear to have a clinical impact on the population of dogs included in this work.
V. Zusammenfassung
Evaluierung des Effekts eines Doxorubicin-beinhaltendes Zyklischen Kombinationschemotherapie-Protokolls auf kardiale Parameter.
Guy Tater
Doxorubicin ist zur Behandlung des malignen Lymphoms des Hundes ein häufig angewendetes Chemotherapeutikum. In hohen Dosen verabreicht kann eine kardiotoxische Wirkung beobachtet werden. Ziel dieser Arbeit war es zu
untersuchen ob, bei Anwendung eines zyklischen Chemotherapie-Protokolls zur Behandlung des canines Lymphoms ein Effekt auf das Herz nach Anwendung dieses Medikaments festgestellt werden kann. Hunde, bei denen die Diagnose canines malignes Lymphom gestellt wurde und die mit einem zyklischen
Chemotherapie-Protokoll mit L-Asparaginase, Vincristin, Cyclophosphamid, Prednisolon und Doxorubicin behandelt wurden, wurden in die Studie eingeschlossen.
Im ersten Teil dieser Arbeit erfolgte die retrospektive Auswertung und Analyse von echokardiographischen Aufnahmen, wobei eine mögliche doxorubicin-induzierte Kardiotoxizität anhand der LVFS untersucht wurde.
Die Aufnahmen von zwischen 2001 und 2010 vorstellig gewordenen Hunden wurden untersucht und insgesamt 446 LVFS Messungen von 108 Hunden in die Studie eingeschlossen. Es konnte kein signifikanter Unterschied der LVFS in den verschiedenen Stadien des chemotherapeutischen Protokolls festgestellt werden.
Der gebräuchliche Referenzwert der LVFS von mindestens 25 % wurde nicht unterschritten.
Der zweite Teil dieser Arbeit umfasste eine prospektive Studie. Ziel dieser Studie war es, sensitivere und ausgereiftere Methoden, die mögliche Veränderungen bzw.
Schäden am Herzen durch das zyklische Kombinationsprotokoll feststellen sollten, zu evaluieren. Vierzehn Hunde wurden eingeschlossen, bei denen zuvor erhöhte Nierenwerte anhand eines Blutbildes ausgeschlossen worden waren. Des Weiteren wurde von allen Studienteilnehmern ein Herzultraschall angefertigt und
ultrasensitives Troponin I vor und nach Doxorubicin-Gabe gemessen.
Die Ultraschalluntersuchung beinhaltete Standard- und Gewebedoppler-Messungen.
Systolische und diastolische Gewebegeschwindigkeiten des interventrikulären Septums und der freien Wand wurden untersucht. Insgesamt wurden 182 Gewebegeschwindigkeits- und 1017 ultrasensitive Troponin I Messungen durchgeführt und bewertet.
Während des zwölfwöchigen zyklischen Kombinationsprotokolls wiesen weder die Gewebedoppler-Messungen noch die Messungen des ultrasensitiven Troponin I signifikante Unterschiede auf.
Ob Doxorubicin einen myokardialen Schaden verursacht sollte anhand
weiterführender prospektiver Studien beurteilt werden, in denen andere sensitive Messmethoden wie die Strain, Strain Rate und das Speckle Tracking zum Einsatz kommen. Auch wenn es innerhalb der Studienpopulation keinen Hinweis gab, lässt sich ein Schaden des Myokards auf zellulärer Ebene durch die eigene Studie nicht mit Sicherheit ausschließen.
VI. Literature
ABBASI, M., A. LAVASANIFAR and H. ULUDAG (2013):
Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.
Medicinal research reviews 33, 33-53
AHMED, N. K., R. L. FELSTED and N. R. BACHUR (1981):
Daunorubicin reduction mediated by aldehyde and ketone reductases.
Xenobiotica; the fate of foreign compounds in biological systems 11, 131-136
AIROLDI, M., G. BARONE, G. GENNARO, A. M. GIULIANI and M. GIUSTINI (2014):
Interaction of doxorubicin with polynucleotides. A spectroscopic study.
Biochemistry 53, 2197-2207
BAUMWART, R. D., J. ORVALHO and K. M. MEURS (2007):
Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy.
Am J Vet Res 68, 524-528
BELHAM, M., A. KRUGER, S. MEPHAM, G. FAGANELLO and C. PRITCHARD (2007):
Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy.
European journal of heart failure 9, 409-414
BOON, J. (1998):
Appendix IV.
In: Manuel of veterinary echocardiography Lippincot Williams and Wilkins, S.
CHETBOUL, V., N. ATHANASSIADIS, C. CARLOS, A. NICOLLE, L. ZILBERSTEIN, J. L. POUCHELON, H. P. LEFEBVRE and D. CONCORDET (2004a):
Assessment of repeatability, reproducibility, and effect of anesthesia on determination of radial and longitudinal left ventricular velocities via tissue Doppler imaging in dogs.
Am J Vet Res 65, 909-915
CHETBOUL, V., N. ATHANASSIADIS, C. CARLOS, A. P. NICOLLE, R. TISSIER, J.
L. POUCHELON, D. CONCORDET and H. P. LEFEBVRE (2004b):
Quantification, repeatability, and reproducibility of feline radial and longitudinal left ventricular velocities by tissue Doppler imaging.
Am J Vet Res 65, 566-572
CHETBOUL, V., S. BLOT, C. C. SAMPEDRANO, J. L. THIBAUD, N. GRANGER, R.
TISSIER, P. BRUNEVAL, F. GASCHEN, V. GOUNI, A. P. NICOLLE and J. L.
POUCHELON (2006a):
Tissue Doppler imaging for detection of radial and longitudinal myocardial dysfunction in a family of cats affected by dystrophin-deficient hypertrophic muscular dystrophy.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 20, 640-647
CHETBOUL, V., C. CARLOS, S. BLOT, J. L. THIBAUD, C. ESCRIOU, R. TISSIER, J. L. RETORTILLO and J. L. POUCHELON (2004c):
Tissue Doppler assessment of diastolic and systolic alterations of radial and longitudinal left ventricular motions in Golden Retrievers during the preclinical phase of cardiomyopathy associated with muscular dystrophy.
Am J Vet Res 65, 1335-1341
CHETBOUL, V., V. GOUNI, C. C. SAMPEDRANO, R. TISSIER, F. SERRES and J.
L. POUCHELON (2007a):
Assessment of regional systolic and diastolic myocardial function using tissue Doppler and strain imaging in dogs with dilated cardiomyopathy.
J Vet Intern Med 21, 719-730
CHETBOUL, V., C. C. SAMPEDRANO, D. CONCORDET, R. TISSIER, T. LAMOUR, J. GINESTA, V. GOUNI, A. P. NICOLLE, J. L. POUCHELON and H. P. LEFEBVRE (2005a):
Use of quantitative two-dimensional color tissue Doppler imaging for assessment of left ventricular radial and longitudinal myocardial velocities in dogs.
Am J Vet Res 66, 953-961
CHETBOUL, V., C. C. SAMPEDRANO, V. GOUNI, D. CONCORDET, T. LAMOUR, J. GINESTA, A. P. NICOLLE, J. L. POUCHELON and H. P. LEFEBVRE (2005b):
Quantitative assessment of regional right ventricular myocardial velocities in awake dogs by Doppler tissue imaging: Repeatability, reproducibility, effect of body weight and breed, and comparison with left ventricular myocardial velocities.
J Vet Intern Med 19, 837-844
CHETBOUL, V., C. C. SAMPEDRANO, V. GOUNI, A. P. NICOLLE and J. L.
POUCHELON (2006b):
Two-dimensional color tissue Doppler imaging detects myocardial dysfunction before occurrence of hypertrophy in a young Maine Coon cat.
Vet Radiol Ultrasoun 47, 295-300
CHETBOUL, V., C. C. SAMPEDRANO, V. GOUNI, A. P. NICOLLE, J. L.
POUCHELON and R. TISSIER (2006c):
Ultrasonographic assessment of regional radial and longitudinal systolic function in healthy awake dogs.
J Vet Intern Med 20, 885-893
CHETBOUL, V., F. SERRES, V. GOUNI, R. TISSIER and J. L. POUCHELON (2007b):
Radial strain and strain rate by two-dimensional speckle tracking echocardiography and the tissue velocity based technique in the dog.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 9, 69-81
CHETBOUL, V., A. TIDHOLM, A. NICOLLE, C. C. SAMPEDRANO, V. GOUNI, J. L.
POUCHELON, H. P. LEFEBVRE and D. CONCORDET (2005c):
Effects of animal position and number of repeated measurements on selected two-dimensional and M-mode echocardiographic variables in healthy dogs.
Journal of the American Veterinary Medical Association 227, 743-747
CHLEBOWSKI, R. T. (1979):
Adriamycin (doxorubicin) cardiotoxicity: a review.
The Western journal of medicine 131, 364-368
CHUN, R., L. D. GARRETT and D. M. VAIL (2007):
Cancer Chemotherapy.
In: Withrow and MacEwen's Small Animal Clinical Oncology WB Saunders, Fourth ed., S. 163-191
CORNELL, C. C., M. D. KITTLESON, P. DELLA TORRE, J. HAGGSTROM, C. W.
LOMBARD, H. D. PEDERSEN, A. VOLLMAR and A. WEY (2004):
Allometric scaling of M-mode cardiac measurements in normal adult dogs.
J Vet Intern Med 18, 311-321
DANDEL, M. and R. HETZER (2009):
Echocardiographic strain and strain rate imaging - Clinical applications.
Int J Cardiol 132, 11-24
DEVEREUX, R. B., E. M. LUTAS, P. N. CASALE, P. KLIGFIELD, R. R. EISENBERG, I. W. HAMMOND, D. H. MILLER, G. REIS, M. H. ALDERMAN and J. H. LARAGH (1984):
Standardization of M-Mode Echocardiographic Left-Ventricular Anatomic Measurements.
J Am Coll Cardiol 4, 1222-1230
DINIZ, P. P., H. S. DE MORAIS, E. B. BREITSCHWERDT and D. S. SCHWARTZ (2008):
Serum cardiac troponin I concentration in dogs with ehrlichiosis.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 22, 1136-1143
DITCHEY, R. V., M. M. LEWINTER and C. B. HIGGINS (1984):
Acute effects of doxorubicin (adriamycin) on left ventricular function in dogs.
Int J Cardiol 6, 341-353
ERBEL, R., D. R. WALLBRIDGE, J. ZAMORANO, J. DROZDZ and H. J. NESSER (1996):
Tissue Doppler echocardiography.
Heart 76, 193-196
FEIGENBAUM, H., W. F. ARMSTRONG and T. RYAN (2005a):
Evaluation of Systolic and Diatolic Function of the Left Ventricle.
In: Feigenbaum´s Echocardiography
Sixth, Lippincot Williams & Wilkins, S. 138-180
FEIGENBAUM, H., W. F. ARMSTRONG and T. RYAN (2005b):
Specialized Echocardiographic Techniques and Methods.
In: Feigenbaum´s Echocardiography
Sixth, Lippincot Williams & Wilkins, S. 46-75
FONFARA, S., J. LOUREIRO, S. SWIFT, R. JAMES, P. CRIPPS and J. DUKES-MCEWAN (2010):
Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs.
Vet J 184, 334-339
GARRETT, L. D., D. H. THAMM, R. CHUN, R. DUDLEY and D. M. VAIL (2002):
Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
J Vet Intern Med 16, 704-709
GOORMAGHTIGH, E., P. CHATELAIN, J. CASPERS and J. M. RUYSSCHAERT (1980):
Evidence of a specific complex between adriamycin and negatively-charged phospholipids.
Biochimica et biophysica acta 597, 1-14
GUSTAFSON, D. L., J. C. RASTATTER, T. COLOMBO and M. E. LONG (2002):
Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model.
Journal of pharmaceutical sciences 91, 1488-1501
HAGMAN, R., A. S. LAGERSTEDT, B. A. FRANSSON, A. BERGSTROM and J.
HAGGSTROM (2007):
Cardiac troponin I levels in canine pyometra.
Acta veterinaria Scandinavica 49, 6
HAMMER, A. S., C. G. COUTO, J. FILPPI, D. GETZY and K. SHANK (1991):
Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 5, 160-166
HRELIA, S., D. FIORENTINI, T. MARALDI, C. ANGELONI, A. BORDONI, P. L. BIAGI and G. HAKIM (2002):
Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes.
Biochimica et biophysica acta 1567, 150-156
HURLEY, L. H. (2002):
DNA and its associated processes as targets for cancer therapy.
Nat Rev Cancer 2, 188-200
KELLER, E. T., E. G. MACEWEN, R. C. ROSENTHAL, S. C. HELFAND and L. E.
FOX (1993):
Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 7, 289-295
KILLICH, M., K. HARTMANN and G. WESS (2011):
[Measuring myocardial velocity using tissue Doppler imaging in healthy dogs].
Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere 39, 69-78
KITTLESON, M. D. and R. D. KIENLE (1998a):
Echocardiography.
In: Small animal cardiovascular medicine eds., Mosby, S. 95-117
KITTLESON, M. D. and R. D. KIENLE (1998b):
Primary myocardial disease leading to chronic myocardial failure - Doxorubicin induced myocardial failure.
In: Smal animal cardiovascular medicine eds., Mosby, S. 340
KLAPPE, K., I. HUMMEL, D. HOEKSTRA and J. W. KOK (2009):
Lipid dependence of ABC transporter localization and function.
Chemistry and physics of lipids 161, 57-64
KURZ, E. U., P. DOUGLAS and S. P. LEES-MILLER (2004):
Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species.
The Journal of biological chemistry 279, 53272-53281
LAVECCHIO, D., L. M. MARIN, R. BAUMWART, M. C. IAZBIK, N. WESTENDORF and C. G. COUTO (2009):
Serum Cardiac Troponin I Concentration in Retired Racing Greyhounds.
J Vet Intern Med 23, 87-90
LI, Z. X., T. T. WANG, Y. T. WU, C. M. XU, M. Y. DONG, J. Z. SHENG and H. F.
HUANG (2008):
Adriamycin induces H2AX phosphorylation in human spermatozoa.
Asian journal of andrology 10, 749-757
LORI, J. C., T. J. STEIN and D. H. THAMM (2010):
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
Veterinary and comparative oncology 8, 188-195
MACEWEN, E. G. (1990):
Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.
Cancer metastasis reviews 9, 125-136
MARGIOCCO, M. L., B. J. BULMER and D. D. SISSON (2009):
Doppler-derived deformation imaging in unsedated healthy adult dogs.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 11, 89-102
MAULDIN, G. E., P. R. FOX, A. K. PATNAIK, B. R. BOND, S. C. MOONEY and R. E.
MATUS (1992):
Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 6, 82-88
MIROSHNYCHENKO, K. V. and A. V. SHESTOPALOVA (2010):
The effect of drug-DNA interactions on the intercalation site formation.
International Journal of Quantum Chemistry 110, 161-176
MISRA, R., M. DAS, B. S. SAHOO and S. K. SAHOO (2014):
Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
International journal of pharmaceutics 475, 372-384
MOISE, N. S. and P. R. FOX (1999):
Echocardiography and Doppler Imaging.
In: Textbook of canine and feline cardiology
WB Saunders, Second ed., Fox P. R., Sisson D., Moise N. S. eds., S. 130-171
MYERS, N. C., 3RD, A. S. MOORE, W. M. RAND, J. GLIATTO and S. M. COTTER (1997):
Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 11, 333-339
NICOLAY, K., R. J. TIMMERS, E. SPOELSTRA, R. VAN DER NEUT, J. J. FOK, Y.
M. HUIGEN, A. J. VERKLEIJ and B. DE KRUIJFF (1984):
The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes.
Biochimica et biophysica acta 778, 359-371
NOLTE, N. and I. NOLTE (2000):
Teil IV Spezielle Onkologie - Tumoren des blutbildenden System.
In: Praxis der Onkologie bei Hund und Katze Enke, Stuttgart, S. 107-132
O'KEEFE, D. A., D. D. SISSON, H. B. GELBERG, D. J. SCHAEFFER and D. R.
KRAWIEC (1993):
Systemic toxicity associated with doxorubicin administration in cats.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 7, 309-317
OGILVIE, G. K., B. E. POWERS, C. H. MALLINCKRODT and S. J. WITHROW (1996):
Surgery and doxorubicin in dogs with hemangiosarcoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 10, 379-384
OGILVIE, G. K., R. C. RICHARDSON, C. R. CURTIS, S. J. WITHROW, H. A.
REYNOLDS, A. M. NORRIS, R. A. HENDERSON, J. S. KLAUSNER, J. D. FOWLER and D. MCCAW (1989):
Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Journal of the American Veterinary Medical Association 195, 1584-1587
OYAMA, M. A. and D. D. SISSON (2004):
Cardiac troponin-I concentration in dogs with cardiac disease.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 18, 831-839
OYAMA, M. A., D. D. SISSON and P. F. SOLTER (2007):
Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations.
Am J Vet Res 68, 42-47
PAGE, R. and B. KEENE (1992):
Doxorubicin cardiomyopathy.
In: : Kirk's Current Veterinary Therapy WB Saunders S. 783
PALAKURTHI, S., V. K. YELLEPEDDI and K. K. VANGARA (2012):
Recent trends in cancer drug resistance reversal strategies using nanoparticles.
Expert opinion on drug delivery 9, 287-301
PAN, S. S. and N. R. BACHUR (1980):
Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation.
Molecular pharmacology 17, 95-99
PICARD, M. H. (1994):
M-mode echocardiography: Principles and examination techniques.
In: Principles and Practice of Echocardiography Lea & Febiger, S. 282, 584
QIU, L., M. QIAO, Q. CHEN, C. TIAN, M. LONG, M. WANG, Z. LI, W. HU, G. LI, L.
CHENG, H. HU, X. ZHAO and D. CHEN (2014):
Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Biomaterials 35, 9877-9887
SALTIEL, E. and W. MCGUIRE (1983):
Doxorubicin (adriamycin) cardiomyopathy.
The Western journal of medicine 139, 332-341
SARDI, I., O. FANTAPPIE, G. LA MARCA, M. G. GIOVANNINI, A. L. IORIO, M. DA ROS, S. MALVAGIA, S. CARDELLICCHIO, L. GIUNTI, M. DE MARTINO and R.
MAZZANTI (2014):
Delivery of doxorubicin across the blood-brain barrier by ondansetron pretreatment: a study in vitro and in vivo.
Cancer letters 353, 242-247
SCHOBER, K. E., C. CORNAND, B. KIRBACH, H. AUPPERLE and G. OECHTERING (2002):
Serum cardiac troponin I and cardiac troponin T concentrations in dogs with gastric dilatation-volvulus.
Journal of the American Veterinary Medical Association 221, 381-388
SELTING, K. A., S. E. LANA, G. K. OGILVIE, A. OLMSTEAD, D. L. MYKLES, J.
BRIGHT, K. L. RICHARDSON, J. A. WALTON, E. MONNET and M. J. FETTMAN (2004):
Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis.
Veterinary and comparative oncology 2, 142-156
SERES, M., D. CHOLUJOVA, T. BUBENCIKOVA, A. BREIER and Z. SULOVA (2011):
Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in l1210 cells.
International journal of molecular sciences 12, 7772-7784
SHAH, H. R., M. VAYNBLAT, G. RAMDEV, J. N. CUNNINGHAM and M.
CHIAVARELLI (1997):
Experimental cardiomyopathy as a model of chronic heart failure.
J Invest Surg 10, 387-396
SIMAK, J., L. KELLER, M. KILLICH, K. HARTMANN and G. WESS (2011):
Color-coded longitudinal interventricular septal tissue velocity imaging, strain and strain rate in healthy Doberman Pinschers.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 13, 1-11
SIMON, D., I. NOLTE, N. EBERLE, N. ABBREDERIS, M. KILLICH and J.
HIRSCHBERGER (2006):
Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
J Vet Intern Med 20, 948-954
SISSON, D., M. O´GRADY and C. CALVERT (1999):
Myocardial diseases of dogs.
In: Textbook of canine and feline cardiology
WB Saunders Second ed.,Fox P. R., Sisson D., Moise N. S. eds., S. 581-619
SORENMO, K. U., J. L. BAEZ, C. A. CLIFFORD, E. MAULDIN, B. OVERLEY, K.
SKORUPSKI, R. BACHMAN, M. SAMLUK and F. SHOFER (2004):
Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 18, 209-213
SUTHERLAND, G. R., G. DI SALVO, P. CLAUS, J. D'HOOGE and B. BIJNENS (2004):
Strain and strain rate imaging: a new clinical approach to quantifying regional myocardial function.
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 17, 788-802
SUTHERLAND, G. R., T. KUKULSKI, J. U. VOIGHT and J. D'HOOGE (1999):
Tissue Doppler echocardiography: Future developments.
Echocardiogr-J Card 16, 509-520
TERASAKI, T., T. IGA, Y. SUGIYAMA and M. HANANO (1982):
Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant.
The Journal of pharmacy and pharmacology 34, 597-600
TEWEY, K. M., T. C. ROWE, L. YANG, B. D. HALLIGAN and L. F. LIU (1984):
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.
Science (New York, N.Y.) 226, 466-468
THOMAS, W. P., C. E. GABER, G. J. JACOBS, P. M. KAPLAN, C. W. LOMBARD, N.
S. MOISE and B. L. MOSES (1993):
Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 7, 247-252
TOYODA, Y., M. OKADA and M. A. KASHEM (1998):
A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration.
J Thorac Cardiov Sur 115, 1367-1373
TRAFNY, D. J., M. A. OYAMA, C. WORMSER, C. A. REYNOLDS, G. E.
SINGLETARY and G. D. PEDDLE (2010):
Cardiac troponin-I concentrations in dogs with bradyarrhythmias before and after artificial pacing.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 12, 183-190
UEMATSU, M., K. MIYATAKE, N. TANAKA, H. MATSUDA, A. SANO, N. YAMAZAKI, M. HIRAMA and M. YAMAGISHI (1995):
Myocardial Velocity-Gradient as a New Indicator of Regional Left-Ventricular Contraction - Detection by a 2-Dimensional Tissue Doppler Imaging Technique.
J Am Coll Cardiol 26, 217-223
VAN VLEET, J. F., V. J. FERRANS and W. E. WEIRICH (1980):
Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.
The American journal of pathology 99, 13-42
WANG, J. C. (1985):
DNA topoisomerases.
Annual review of biochemistry 54, 665-697
WELLS, S. M. and M. SLEEPER (2008):
Cardiac troponins.
J Vet Emerg Crit Car 18, 235-245
WESS, G., L. J. KELLER, M. KLAUSNITZER, M. KILLICH and K. HARTMANN (2011):
Comparison of longitudinal myocardial tissue velocity, strain, and strain rate measured by two-dimensional speckle tracking and by color tissue Doppler imaging in healthy dogs.
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology 13, 31-43
WESS, G., M. KILLICH and K. HARTMANN (2010a):
Comparison of pulsed wave and color Doppler myocardial velocity imaging in healthy dogs.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 24, 360-366
WESS, G., J. MAURER, J. SIMAK and K. HARTMANN (2010b):
Use of Simpson's Method of Disc to Detect Early Echocardiographic Changes in Doberman Pinschers with Dilated Cardiomyopathy.
J Vet Intern Med 24, 1069-1076
WESS, G., J. SIMAK, M. MAHLING and K. HARTMANN (2010c):
Cardiac troponin I in Doberman Pinschers with cardiomyopathy.
Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 24, 843-849
VII. Tables and figures for Chapter II.1
Abb. 1 Right parasternal long axis view depicting an M-Mode. The cursor is placed along the long and short axis view at end diastole and end systole. IVSd = intraventricular septum diameter in diastole, IVSs = intraventricular septum diameter in systole, LVIDd = left ventricular inner diameter in the diastole, LVIDs = left ventricular inner diameter in the systole, LVPWd = left ventricular posterior wall diameter in diastole, LVPWs = left ventricular posterior wall diameter in systole, FS = left ventricular fractional shortening.
Tab. 1 12-week chemotherapy protocol used for the treatment of canine lymphoma as described by Simon et al.
Week
Drug Dose 1 2 3 4 5 6 7 8 9 10 11 12 13
L-asparaginasea 400 IU/kg SC ●
Vincristine 0.7 mg/m2 IV ● ● ● ●
Cyclophosphamide 200 mg/m2 IV ● ● ● ●
Doxorubicinb 30 mg/m2 IV* ● ● ● ●
Prednisolone
50 mg/m2 PO q24h for 3
days ● ● ● ● ● ● ● ● ● ● ● ●
Echocardiography ● ● ● ● ●
IV, intravenous administration; IV*, intravenous infusion over 30 min; PO, oral administration
aPretreatment with prednisolon
bAdministration of prednisolone on days 1-3
Tab. 2 Table showing left ventricular fractional shortening (LVFS) changes of the four groups during the cyclic combination chemotherapy protocol including doxorubicin.
Groups Measurement LVFS (min-max)
Group 1 (one DT) (n = 7) median baseline LVFS (%) 33 (26-40) median LVFS post 1 DT (%) 30 (27-37) Group 2 (two DT) (n = 17) median baseline LVFS (%) 33 (20-49) median LVFS post 1 DT (%) 34 (25-43) median LVFS post 2 DT (%) 31 (25-43) Group 3 (three DT) (n = 39) median baseline LVFS (%) 35 (24-50) median LVFS post 1 DT (%) 34 (25-50) median LVFS post 2 DT (%) 34 (25-50) median LVFS post 3 DT (%) 32 (22-43) Group 4 (four DT) (n = 45) median baseline LVFS (%) 32 (22-49) median LVFS post 1 DT (%) 32 (24-54)
Group 1 (one DT) (n = 7) median baseline LVFS (%) 33 (26-40) median LVFS post 1 DT (%) 30 (27-37) Group 2 (two DT) (n = 17) median baseline LVFS (%) 33 (20-49) median LVFS post 1 DT (%) 34 (25-43) median LVFS post 2 DT (%) 31 (25-43) Group 3 (three DT) (n = 39) median baseline LVFS (%) 35 (24-50) median LVFS post 1 DT (%) 34 (25-50) median LVFS post 2 DT (%) 34 (25-50) median LVFS post 3 DT (%) 32 (22-43) Group 4 (four DT) (n = 45) median baseline LVFS (%) 32 (22-49) median LVFS post 1 DT (%) 32 (24-54)